CHICAGO--(BUSINESS WIRE)--The Medicines Company (Nasdaq: MDCO - News) today announced that Angiomax® (bivalirudin) resulted in improved net adverse clinical outcomes and reduced the risk of major bleeding despite the sex, age, diabetes status or renal function of heart attack patients in the HORIZONS-AMI trial compared to a more complex treatment regimen 30 days following primary angioplasty. These data from the landmark global trial were presented today at the SCAI Annual Scientific Session in Partnership with ACCi2. Angiomax is available in Europe as Angiox®.
